Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Nov 2011

Popat Sanjay, Vieira de Araújo Alexandra, Min Toon, Swansbury John, Dainton Melissa, Wotherspoon Andrew, Lim Eric, Nicholson Andrew G, O'Brien Mary E R

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Anaplastic Lymphoma Kinase
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gene Rearrangement

Share to Lung Neoplasms

Share to Quinazolines

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 22005476
DOI: 10.1097/JTO.0b013e31822eec5e

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.PMID 22005476Read ↗

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.Semantic proximity Read ↗

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.Semantic proximity Read ↗

EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report.Semantic proximity Read ↗

First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component.Semantic proximity Read ↗

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient.Semantic proximity Read ↗

Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.Semantic proximity Read ↗

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.Semantic proximity Read ↗

A rare EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma: a favorable response to afatinib.Semantic proximity Read ↗

Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells.Semantic proximity Read ↗

[Management of a patient with a double EGFR and MET anomaly by combined treatment].Semantic proximity Read ↗

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.Semantic proximity Read ↗

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.